Join
Live feed
·
PRReleasevia Quantisnow
Zenas BioPharma Inc. logo

Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor

ByQuantisnow·Wall Street's wire, on your screen.
ZBIO· Zenas BioPharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ZBIO (Zenas BioPharma Inc.) and more on Quantisnow.